Studies of Myo-inositol and Plasmalogen Metabolism in Rat Brain

Hoffman-Kuczynski, Beth; Reo, Nicholas V.

doi:10.1023/b:nere.0000018859.23881.f9

Cited by 12 publications

(59 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The addition of Etn containing 13 C isotope enrichment enabled us to monitor the biosynthesis of Etn lipids in the brain by NMR. Our results demonstrated that the acute myo-Ins + Etn administration yielded a 30% increase in whole brain PlsEtn concentrations, a 16% increase in its mole percentage of phospholipids and a 47% increase in the biosynthesis of newly synthesized Etn lipids (12). We also demonstrated a strong positive correlation between the brain myoIns concentration and PlsEtn concentration.…”

Section: Introductionsupporting

confidence: 62%

See 1 more Smart Citation

Administration of Myo-inositol Plus Ethanolamine Elevates Phosphatidylethanolamine Plasmalogen in the Rat Cerebellum

Hoffman-Kuczynski

Reo

2005

Neurochem Res

Self Cite

View full text Add to dashboard Cite

Plasmalogens are ether-linked phospholipids highly abundant in nervous tissue. Previously we demonstrated that acute administration of myo-inositol (myo-Ins) + [2-(13)C] ethanolamine ([2-(13)C]Etn) significantly elevated phosphatidylethanolamine plasmalogen (PlsEtn) in rat whole brain. Current experiments investigated the effects of acute myo-Ins+[2-(13)C]Etn administration on [PlsEtn] and the biosynthesis of new Etn lipids using NMR spectroscopy in rat cerebral cortex, hippocampus, brainstem, midbrain and cerebellum. Treated rats received a single dose of myo-Ins + [2-(13)C]Etn and controls received saline rather than myoIns. Data reveal that the cerebellum is the brain region most affected by treatment, which resulted in a 22% increase in [PlsEtn] and 89% increase in newly synthesized Etn lipids relative to controls (P < 0.05). Furthermore, the cerebellar PlsEtn/phosphatidylethanolamine ratio and molar percentage of PlsEtn were significantly elevated by 12% and 8%, respectively (P < 0.05). These data suggest that myo-Ins influences Etn lipid metabolism in brain, particularly in the cerebellum where there is a stimulation in the biosynthesis of new Etn lipids with a preference towards PlsEtn.

show abstract

Section: Introductionsupporting

confidence: 62%

“…Recently, our laboratory further investigated this phenomenon using several protocols involving chronic and acute administration of myo-Ins ± ethanolamine (Etn) in rats (12). The addition of Etn containing 13 C isotope enrichment enabled us to monitor the biosynthesis of Etn lipids in the brain by NMR.…”

Section: Introductionmentioning

confidence: 99%

Administration of Myo-inositol Plus Ethanolamine Elevates Phosphatidylethanolamine Plasmalogen in the Rat Cerebellum

Hoffman-Kuczynski

Reo

2005

Neurochem Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…The increased ratio of plasmalogens to phospholipids (Plas/PL) after myo-inositol treatment was greater than that of the actual plasmalogen level (Table 2), which means a specific enhancement of plasmalogen biosynthesis in glycerophospholipids. Myo-inositol is reported to increase the brain plasmalogen content in rats (10), and this effect may contribute to improve affective disorders, such as major depression and panic disorder (11). Although the mechanism by which myo-inositol enhances plasmalogen biosynthesis remains unknown, myo-inositol intake possibly facilitates plasmalogen biosynthesis in the liver, and this may lead to the secretion of plasmalogen-rich lipoproteins.…”

Section: Discussionmentioning

confidence: 99%

Myo-Inositol Treatment Increases Serum Plasmalogens and Decreases Small Dense LDL, Particularly in Hyperlipidemic Subjects with Metabolic Syndrome

Maeba

Hara

Ishikawa

et al. 2008

J Nutr Sci Vitaminol

View full text Add to dashboard Cite

Summary Background and aim: We have previously shown that serum plasmalogen levels positively correlate with HDL, and significantly decrease with aging, and may be related to LDL particle size. The objective of the present study was to investigate the effects of increased serum plasmalogens on lipidosis, particularly the appearance of atherogenic small dense LDL (sdLDL), of subjects with hyperlipidemia and metabolic syndrome (MetS). Methods and results: The effects of increased serum plasmalogen levels, induced by 2 wk of myoinositol treatment, on several clinical and biochemical parameters were examined in 17 hyperlipidemic subjects including some with MetS. After myo -inositol treatment, significant increases in plasmalogen-related parameters, particularly ChoPlas, and significant decreases in atherogenic cholesterols including sdLDL, were observed. Among the hyperlipidemic subjects treated with myo -inositol, compared to subjects without MetS, subjects with MetS had a significant increase in plasmalogens and a tendency towards reduced sdLDL, high sensitivity C-reactive protein (hsCRP), and blood glucose levels. Correlation analyses between the measured parameters showed that plasmalogens, as well as HDL, function as beneficial factors, and that sdLDL is a very important risk factor that shows positive correlations with many other risk factors. Conclusion: These results suggest that increased plasmalogen biosynthesis and/or serum levels are especially effective in improving MetS among hyperlipidemic subjects with MetS. Key Words plasmalogens, metabolic syndrome, small dense low-density lipoprotein, myoinositol Plasmalogens (1-alkenyl-2-acyl-sn -glycero-3-phospholipids) in serum are biosynthesized in the liver and secreted into circulating blood as lipoprotein components. Several studies have shown that plasmalogen levels in the plasma or red blood cell membranes decrease with aging or in the presence of hyperlipidemia ( 1 ); plasmalogen levels are decreased in the lowdensity lipoprotein (LDL) of familial hypercholesterolemia patients ( 2 ). However, large scale clinical studies have not yet been done, because the conventional methods used to determine plasmalogens are laborious and unsuitable for highly sensitive quantification.Recently, we established a highly sensitive and convenient method for quantifying choline plasmalogen (ChoPlas) and ethanolamine plasmalogen (EtnPlas) separately ( 3 ). Using this new method, we quantified the serum plasmalogen levels of approximately 300 subjects, and analyzed the correlations of serum plasmalogens with clinical markers and serum biochemical markers. The following results were obtained: i) serum plasmalogens decrease markedly with aging; ii) serum plasmalogen levels are positively correlated with highdensity lipoprotein (HDL); and iii) the ratio of ChoPlas to EtnPlas is positively correlated with LDL particle size ( 4 ). These results suggest that serum plasmalogens, as well as HDL, function as beneficial factors, and furthermore that plasmalogen biosynthesis and/or se...

show abstract

“…Pls are major component of myelin membranes, and essential for myelin formation and functions. In animal studies, oral administration of MI showed to increase Pls level in rat brain (Hoffman-Kuczynski & Reo, 2004). Therefore, we have undertaken MI intervention study to investigate whether MI administration improves the dyslipidemia of MetS through facilitating Pls biosynthesis, and to explore the relationship between serum Pls and sdLDL.…”

Section: Intervention Study Of Increasing Serum Plsmentioning

confidence: 99%